Literature DB >> 9336015

Therapeutic drug monitoring opportunities in cancer therapy.

H L McLeod1.   

Abstract

Cancer is a common cause of death, and improvements in treatment are desperately needed. The high degree of variation in systemic exposure for a given dose and the relationships between blood concentrations and either toxic or antitumor effects would suggest that therapeutic drug monitoring is a potential mechanism for improving the treatment of individual patients. In this review, the case for therapeutic drug monitoring is made in a select number of commonly used cancer drugs and areas that require more concerted effort are highlighted.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9336015     DOI： 10.1016/s0163-7258(96)00201-x

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN： 0163-7258            Impact factor:   12.310


  9 in total

Review 1.  CHIP and gp78-mediated ubiquitination of CYP3A4: Implications for the pharmacology of anticancer agents.

Authors:  Cody J Peer; Tristan M Sissung; William D Figg
Journal:  Cancer Biol Ther       Date:  2011-03-15       Impact factor: 4.742

Review 2.  Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review.

Authors:  Milly E de Jonge; Alwin D R Huitema; Jan H M Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 3.  Clinically relevant drug-drug interactions in oncology.

Authors:  H L McLeod
Journal:  Br J Clin Pharmacol       Date:  1998-06       Impact factor: 4.335

Review 4.  Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine.

Authors:  Stefanie L Groenland; Ron H J Mathijssen; Jos H Beijnen; Alwin D R Huitema; Neeltje Steeghs
Journal:  Eur J Clin Pharmacol       Date:  2019-06-07       Impact factor: 2.953

5.  Therapeutic drug monitoring and tyrosine kinase inhibitors.

Authors:  Pauline Herviou; Emilie Thivat; Damien Richard; Lucie Roche; Joyce Dohou; Mélanie Pouget; Alain Eschalier; Xavier Durando; Nicolas Authier
Journal:  Oncol Lett       Date:  2016-06-24       Impact factor: 2.967

Review 6.  Therapeutic drug monitoring databases for postmarketing surveillance of drug-drug interactions.

Authors:  M Gex-Fabry; A E Balant-Gorgia; L P Balant
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 7.  Plasma concentration monitoring of busulfan: does it improve clinical outcome?

Authors:  J S McCune; J P Gibbs; J T Slattery
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

Review 8.  Utility of a next-generation framework for assessment of genomic damage: A case study using the pharmaceutical drug candidate etoposide.

Authors:  John Nicolette; Mirjam Luijten; Jennifer C Sasaki; Laura Custer; Michelle Embry; Roland Froetschl; George Johnson; Gladys Ouedraogo; Raja Settivari; Veronique Thybaud; Kerry L Dearfield
Journal:  Environ Mol Mutagen       Date:  2021-11-22       Impact factor: 3.579

9.  A pilot study on the impact of known drug-drug interactions in cancer patients.

Authors:  Silvia Ussai; Riccardo Petelin; Antonio Giordano; Mario Malinconico; Donatella Cirillo; Francesca Pentimalli
Journal:  J Exp Clin Cancer Res       Date:  2015-08-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.